Business ❯ Healthcare ❯ Pharmaceuticals

Acquisitions

Johnson & Johnson Biogen Novo Nordisk Neurocrine Biosciences AstraZeneca Melinta Therapeutics US WorldMeds Metsera Gilead Sciences Sanofi

Roche to Acquire PathAI for $750 Million Upfront Plus Up to $300 Million in Milestones

The companies expect to close in the second half of 2026 pending required approvals.

Neurocrine to Acquire Soleno for $2.9 Billion in All-Cash Tender

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

CorMedix Shares Jump After Q3 Beat as Company Lifts 2025 Outlook

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

DoorDash Signs Multi-Year Deal to Use Serve Robotics’ Sidewalk Bots for Deliveries

Lupin’s Nanomi to Acquire VISUfarma for €190 Million to Expand European Eye‑Care Portfolio

Adaptimmune Sells Tecelra and Late-Stage Cell Therapies to U.S. WorldMeds for $55M

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

Merck Announces €3 Billion Acquisition of Springworks Therapeutics

Sanofi Secures $1.9 Billion Deal for Dren Bio’s Innovative Autoimmune Therapy

SpringWorks Shares Surge on Reported Acquisition Talks with Merck KGaA

Johnson & Johnson to Acquire Intra-Cellular Therapies in $14.6 Billion Deal

Organon Acquires Dermavant from Roivant for Up to $1.2 Billion